Search

Displaying results 2801 - 2810 of 10000 in total
  1. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PMS-nylidrin Tab 6mg
  2. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)

    Categories: Receptors, Interleukin-1 Type I, Interleukin-1 BlockersSynonyms: interleukin-1 (IL-1) trap, IL-1 TRAP
  3. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). … VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

  4. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2. … [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  6. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. … Midecamycin is a naturally occurring 16-membered macrolide [A33072] that fits under the category of acetoxy-substituted macrolide antibiotics.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: Espinomycin A
  7. Drug

    Nifuratel

    go.drugbank.com/drugs/DB13724
    Investigational

    Mixtures: NİFUNİS 500 MG/200.000 I.U. VAJİNAL OVÜL, 6 ADET, NİFUNİS 500 MG/200.000 I.U. VAJİNAL OVÜL, 12 ADETCategories: Heterocyclic Compounds, 1-Ring, Genito Urinary System and Sex Hormones
  8. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    , and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis). … Growth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics

    Synonyms: L-alanyl-l-histidyl-3-(2-naphthalenyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide, Ala-his-3-(2-naphthalenyl)-d-ala-ala-trp-d-phe-lys-nh2
  9. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    Linopristin is an antibiotic of the streptogramin B class. It is one part of the combination product NXL 103, along with [Virginiamycin M1].

  10. Drug

    Vibostolimab

    go.drugbank.com/drugs/DB16420
    Investigational

    Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK